Immunotherapy of breast cancer by single delivery with rAAV2-mediated interleukin-15 expression

ASIAIR > College of Medical and Health Science > Department of Biotechnology > Journal Article > Item 310904400/16396

Please use this identifier to cite or link to this item: http://asiair.asia.edu.tw/ir/handle/310904400/16396

Title:	Immunotherapy of breast cancer by single delivery with rAAV2-mediated interleukin-15 expression
Authors:	余永倫;Yu, Yung-luen;WEI, CHYOU-WEI;CHEN, YI-LIN;CHEN, MARK HUNG-CHIH;YIANG, GIOU-TENG
Contributors:	生物科技學系
Date:	2010-02
Issue Date:	2012-11-23 09:12:31 (UTC+0)
Abstract:	Recombinant adenovirus-associated vector serotype 2 (rAAV2) is one of the most promising gene transfer vectors due to its advantage of causing non-pathogenic infection, low immunogenicity, and long-term gene expression in human clinical trials. Human interleukin 15 (hIL15) has been implicated in modulation of antitumor activity of lymphokine-activated killer (LAK) cells, including T cells and NK cells. In this study, the rAAV2-hIL15 vector was produced and subjected for treatment with xenograft JC breast cancer model. Results showed that tumor onset was significantly delayed, the tumor growth was suppressed, and the lifespan of tumor-bearing mice were prolonged by rAAV2-hIL15. In addition, rAAV2-hIL15 was able to produce a substantial expression of IL15 protein that ultimately activated the cytotoxic activity of LAK cells. Furthermore, prominent apoptosis was observed in tumor lesions following injection of rAAV2-hIL15. Taken together, our results suggested that rAAV2-hIL15 appears as a new potential therapeutic tool for breast cancer immunotherapy.
Relation:	INTERNATIONAL JOURNAL OF ONCOLOGY
Appears in Collections:	[Department of Biotechnology] Journal Article

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	349	View/Open